No Data
No Data
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
Express News | Apogee Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results
Promising Advancements and Strategic Positioning Propel Apogee Therapeutics, Inc. to a Buy Rating
Apogee Therapeutics | 8-K: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results